For NTRK gene fusion‐positive patients with solid tumors, treatment with TRK inhibitors such as Larotrectinib and Entrectinib, or participation in TRK inhibitor‐related clinical trials is recommended. For NTRK gene fusion‐positive tumor patients with drug resistance, performing NGS tests to identify resistant‐causing mutations and deciding whether or not second‐generation TRK inhibitors or related clinical trials are appropriate are recommended. Here, TPM3 is linked to neoplasm.